4 days ago
Panacea Biotec's EmulsiPan listed in CEPI Adjuvant Library to support vaccine development
Panacea Biotec Limited has announced the inclusion of its adjuvant, EmulsiPan, in the Coalition for Epidemic Preparedness Innovations (CEPI) Library of adjuvants. This listing aims to support researchers and developers working on vaccines and biotherapeutics.
EmulsiPan is an oil-in-water emulsion adjuvant created through the nano-emulsification of squalene, surfactants, and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in plants and humans. EmulsiPan is supplied as a ready-to-use sterile emulsion in 10 mL USP Type I glass vials, intended for research purposes. It is stable for over two years when stored between 2-8°C.
The global market for adjuvants is projected to exceed $4.8 billion by 2028, driven by applications in vaccines and biological therapies, including oncology. Oil-in-water emulsion adjuvants, such as EmulsiPan, are commonly used in commercial vaccines, including influenza vaccines. EmulsiPan's availability without licensing fees provides an accessible option for vaccine developers.
EmulsiPan has been used in various preclinical studies and collaborative research projects. Notably, it was applied in non-human primate challenge studies for Sarbecoronavirus vaccine candidates at the California Institute of Technology (Caltech) and in Betacoronavirus vaccine development programs in partnership with BRIC-Translational Health Science and Technology Institute (THSTI), funded by CEPI. These studies demonstrate its adaptability and effectiveness in vaccine research.
Developed in 2009 and first commercialized as part of Panacea Biotec's H1N1 vaccine, PandyFlu, EmulsiPan has since become a platform adjuvant for multiple vaccine candidates. Panacea Biotec established a cGMP manufacturing facility for EmulsiPan, ensuring consistent quality and regulatory compliance.
The inclusion of EmulsiPan in the CEPI Adjuvant Library confirms it has undergone scientific evaluation and meets standards necessary to support human vaccine development. This listing is expected to increase access for researchers and companies interested in using EmulsiPan for commercial or research applications.
By offering a stable, ready-to-use formulation and removing licensing fees, Panacea Biotec aims to facilitate equitable access to vaccine adjuvants and contribute to global preparedness for future epidemics and pandemics.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
